REVHD

Resveratrol and Huntington Disease

Completed

ABOUT

SPONSOR

Assistance Publique - Hôpitaux de Paris

PARTICIPANTS

102

The main purpose of REVHD is to evaluate the therapeutic potential of Resveratrol on the caudate volume (area located near the center of the brain) in Huntington’s disease (HD) patients, using volumetric MRI. This trial aims to test for a reduction in neurodegeneration among HD patients.

Completion Date: January 2020

Learn More

Ages Eligible for Study:

18 Years and older (Adult, Older Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Inclusion Criteria

  • Positive genetic test with CAG repeat length > or = 39 in HTT gene
  • At least 18 years of age
  • Signature of the informed consent
  • Covered by social security
  • UHDRS score between 5 and 40 (both included)
  • Ability to undergo MRI scanning

Exclusion Criteria

  • Hypersensitivity to resveratrol or to one of its excipients (gelatin and glycerin)
  • Tetrabenazine treatment
  • Neuroleptic treatments other than olanzapine at small doses (≤10 mg) and Abilify® (≤15mg)
  • VKA treatment (Previscan®, Sintron®, Coumadine®)
  • NACO treatment (Pradaxa®, Xarelto®, Eliquis®)
  • Additional psychiatric or neurological conditions
  • Severe head injury
  • Participation in another therapeutic trial (3 months exclusion period)
  • Pregnancy and breastfeeding
  • Inability to understand information about the protocol
  • Persons deprived of their liberty by judicial or administrative decision
  • Adult subject under legal protection or unable to consent.

COUNTRIES

FRANCE

TRIAL SITE:
Institut du Cerveau et de la Moelle, Hôpital de la Pitié Salpêtrière

Address: Paris, France, 75013

CONTACT
Fanny Mochel
Tel: Not available

Not Recruiting